Novo Nordisk (NYSE: NVO), the company behind the popular weight-loss treatment Wegovy and diabetes medication Ozempic (also used by many for weight loss), has been a buy in recent years. Currently, it's trading at a 52-week high, and sales have been soaring. With a bright future ahead, does the stock have what it takes to be a millionaire-making investment?

Sales have taken off for Novo Nordisk, largely due to the strength of its obesity care treatments, which doubled in revenue last year. For five years, the company's sales have been rising sharply:

Continue reading

Source Fool.com